GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Korro Bio Inc (NAS:KRRO) » Definitions » Return-on-Tangible-Equity

Korro Bio (Korro Bio) Return-on-Tangible-Equity : 0.00% (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Korro Bio Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Korro Bio's annualized net income for the quarter that ended in Jun. 2023 was $-74.51 Mil. Korro Bio's average shareholder tangible equity for the quarter that ended in Jun. 2023 was $-117.21 Mil. Therefore, Korro Bio's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2023 was N/A%.

The historical rank and industry rank for Korro Bio's Return-on-Tangible-Equity or its related term are showing as below:

KRRO' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -229.04   Med: -229.04   Max: -229.04
Current: -229.04

During the past 3 years, Korro Bio's highest Return-on-Tangible-Equity was -229.04%. The lowest was -229.04%. And the median was -229.04%.

KRRO's Return-on-Tangible-Equity is ranked worse than
88.1% of 1303 companies
in the Biotechnology industry
Industry Median: -46.56 vs KRRO: -229.04

Korro Bio Return-on-Tangible-Equity Historical Data

The historical data trend for Korro Bio's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Korro Bio Return-on-Tangible-Equity Chart

Korro Bio Annual Data
Trend Dec21 Dec22 Dec23
Return-on-Tangible-Equity
- - -229.04

Korro Bio Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Return-on-Tangible-Equity - - - - -508.99

Competitive Comparison of Korro Bio's Return-on-Tangible-Equity

For the Biotechnology subindustry, Korro Bio's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Korro Bio's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Korro Bio's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Korro Bio's Return-on-Tangible-Equity falls into.



Korro Bio Return-on-Tangible-Equity Calculation

Korro Bio's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-81.172/( (-99.031+169.911 )/ 2 )
=-81.172/35.44
=-229.04 %

Korro Bio's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=-74.508/( (-99.031+-135.397)/ 2 )
=-74.508/-117.214
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Korro Bio  (NAS:KRRO) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Korro Bio Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Korro Bio's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Korro Bio (Korro Bio) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
One Kendall Square, Suite 6-401, Building 600-700, Cambridge, MA, USA, 02139
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Executives
David L. Lucchino director, officer: President and CEO C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Rick Yang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Edward T Mathers 10 percent owner C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Nessan Bermingham director 890 WINTER STREET, WALTHAM MA 02451
Atlas Venture Associates Xi, Llc 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
New Enterprise Associates 17, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 17, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea 17 Gp, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund Ii, L.p. 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Llc 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Lp 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Steve Colletti officer: Chief Scientific Officer C/O KORRO BIO, INC., ONE KENDALL SQUARE, BUILDING 600-700, CAMBRIDGE MA 02139
Shelby J. Walker officer: See Remarks C/O KORRO BIO, INC., ONE KENDALL SQUARE, BUILDING 600-700, CAMBRIDGE MA 02139

Korro Bio (Korro Bio) Headlines

From GuruFocus

Korro Announces $70 Million Private Placement

By Marketwired 04-18-2024